Form 13-F position report

PHOENIX BIOTECH ACQUISITION

Reported by Schonfeld Strategic Advisors LLC

CEROW CUSIP 71902K113 Manager CIK 0001665241

Reported 36,000 shares, unchanged from the prior quarter.

Reported value -48.3%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value < 0.01% This manager · Q4 2022
Shares 36,000 Quarter-end amount reported
Reported value $1,552 Fair value at quarter end
Consecutive quarters held 3 Through Q4 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-06-30 4000
2022-09-30 3000
2022-12-31 1552
2023-03-31 1441
2023-06-30 2356
2023-09-30 2389
2023-12-31 917
2024-03-31 1364
2024-06-30 301
2024-09-30 76
2024-12-31 124
2025-03-31 217
2025-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for PHOENIX BIOTECH ACQUISITION held by Schonfeld Strategic Advisors LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2025 Reduced 0 -15,000 (-100.0%) 0 $0 2025-08-14
Q1 2025 Unchanged 15,000 0 (0.0%) < 0.01% $217 2025-05-15
Q4 2024 Unchanged 15,000 0 (0.0%) < 0.01% $124 2025-02-14
Q3 2024 Unchanged 15,000 0 (0.0%) < 0.01% $76 2024-11-14
Q2 2024 Reduced 15,000 -5,000 (-25.0%) < 0.01% $301 2024-08-14
Q1 2024 Reduced 20,000 -13,373 (-40.1%) < 0.01% $1,364 2024-05-15
Q4 2023 Unchanged 33,373 0 (0.0%) < 0.01% $917 2024-02-14
Q3 2023 Reduced 33,373 -2,627 (-7.3%) < 0.01% $2,389 2023-11-14
Q2 2023 Unchanged 36,000 0 (0.0%) < 0.01% $2,356 2023-08-14
Q1 2023 Unchanged 36,000 0 (0.0%) < 0.01% $1,441 2023-05-15
Q4 2022 Unchanged 36,000 0 (0.0%) < 0.01% $1,552 2023-02-14
Q3 2022 Unchanged 36,000 0 (0.0%) < 0.01% $3,000 2022-11-14
Q2 2022 New 36,000 +36,000 (0.0%) < 0.01% $4,000 2022-08-15

Who else reported the position

57 managers reported PHOENIX BIOTECH ACQUISITION for Q4 2022.

Managers reporting PHOENIX BIOTECH ACQUISITION in Q4 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
MANGROVE PARTNERS Unchanged 163,538 0 0.09% $1,679,584 5 qtrs
Radcliffe Capital Management L P Unchanged 150,000 0 0.05% $1,540,545 5 qtrs
Segantii Capital Management Ltd Unchanged 5,000 0 < 0.01% $51,000 5 qtrs
Periscope Capital Inc Added 957,098 +26,300 < 0.01% $40,600 4 qtrs
HIGHBRIDGE CAPITAL MANAGEMENT LLC Reduced 495,194 -177,414 < 0.01% $21,000 5 qtrs
MMCAP International Inc SPC Unchanged 375,000 0 < 0.01% $16,162 5 qtrs
CANTOR FITZGERALD L P Unchanged 363,548 0 < 0.01% $16,000 5 qtrs
Shaolin Capital Management LLC New 374,998 +374,998 < 0.01% $16,000 1 qtr
CLEAR STREET LLC Added 355,185 +16,467 < 0.01% $15,000 5 qtrs
Polar Asset Management Partners Inc Unchanged 300,000 0 < 0.01% $12,930 5 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2022
Filed
February 14, 2023
Filing type
13F-HR
Position type
*W EXP 09/01/202

Voting authority reported

Sole
0
Shared
0
None
36,000

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.